∙ To be eligible to participate in this study, an individual must meet all the following criteria:

• Provision of signed and dated informed consent form

• Stated willingness to comply with all study procedures and availability for the duration of the study

• Male or female, aged 30 years or greater

• FEV1/FVC of \< 70% and an FEV1 of \< 80% (GOLD stages II - IV, Grade E)

• • Spirometry performed during the screening visit will be used to confirm GOLD stage. A prior spirometric test within the past 6 months can be substituted if available.

• MRC ≥ 2 or CAT ≥ 10

• Former smokers or current smokers and never-smokers are eligible for study inclusion

• • Current smokers must refrain from smoking when using supplemental oxygen or the myAirvo-3 device

• History of a severe COPD exacerbation requiring hospitalization in the previous six weeks

• COPD in a stable state after hospitalization defined as:

‣ Clinically stable condition and have had no parenteral therapy for 24 hours.

⁃ Inhaled bronchodilators are required less than four-hourly.

⁃ Oxygen delivery has ceased for 24 hours (unless home oxygen is indicated).

⁃ If previously able, the patient is ambulating safely and independently, and performing activities of daily living.

⁃ The patient can eat and sleep without significant episodes of dyspnea.

⁃ The patient or caregiver understands and can administer medications.

⁃ Follow-up and home care arrangements (e.g., home oxygen, homecare, Meals on Wheels, community nurse, allied health, GP, specialist) have been completed.

• Willing to adhere to the daily use of the myAirvo 3 regimen for at least 8 hours each day preferably at night following being shown and using the device

⁃ Willing to record daily symptoms and pulse oximetry and heart rate on daily basis

⁃ For females of reproductive potential: use of highly effective contraception for at least 1 month prior to screening and agreement to use such a method during study participation

⁃ Highly effective contraception is defined as:

‣ A tubal ligation:

‣ An approved hormonal contraceptive such as oral contraceptives, emergency contraception used as directed, patches, implants, injections, rings or intrauterine devices

⁃ Able to read and communicate in English

⁃ Have a home environment suitable for myAirvo 3 use.

⁃ Agreement to adhere to Lifestyle Considerations (see section 5.3) throughout study duration - refraining from smoking while receiving supplemental oxygen or the myAirvo-3 device